Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy
British Journal of Haematology · 2024-12 · 205 (6) · 2287-2294
DOI: 10.1111/bjh.19813 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 07.10.2024. Verfasst von Tiziano Barbui und 10 weiteren Autor:innen. Beteiligte Einrichtung: FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy. Hauptthemen laut MEDLINE: Interferon alpha-2, Interferon-alpha, Janus Kinase 2, Lymphocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: AOP Health, Fondazione AIRC per la Ricerca sul Cancro ETS, MYeloid NEoplasms Research Venture AIRC.
Abstract (Originalsprache)
We investigated the effect of Ropeginterferon alfa‐2b (Ropeg) versus phlebotomy‐only (Phl‐O) on the neutrophil‐to‐lymphocyte ratio (NLR) in 126 patients randomized in the low‐polycythaemia vera (PV) phase II trial. Patients with a baseline NLR ≥3.5 vs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell'Adulto, Università di Modena-Reggio Emilia, Modena, Italy.
- CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
- Institute of Hematology, Catholic University, Rome, Italy.
- Fondazione Policlinico Universitario A. Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
- Divisione di Ematologia, ASST Papa Giovanni XXIII, Bergamo, Italy.
ORCID-Profile: Tiziano Barbui, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Valerio De Stefano, Alessandro M Vannucchi
Förderung
- AOP Health
- Fondazione AIRC per la Ricerca sul Cancro ETS
- MYeloid NEoplasms Research Venture AIRC
- BCC Milano
Zitieren
APA
Barbui, T., Carobbio, A., Guglielmelli, P., Ghirardi, A., Fenili, F., Loscocco, G. G., De Stefano, V., Ramundo, F., Finazzi, M. C., Rambaldi, A., & Vannucchi, A. M. (2024). Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy. British Journal of Haematology, 205(6), 2287-2294. https://doi.org/10.1111/bjh.19813
Vancouver
Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, et al. Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy. British Journal of Haematology. 2024;205(6):2287-2294. doi:10.1111/bjh.19813
BibTeX
@article{Barbui2024,
author = {Barbui, Tiziano and Carobbio, Alessandra and Guglielmelli, Paola and Ghirardi, Arianna and Fenili, Francesca and Loscocco, Giuseppe Gaetano and De Stefano, Valerio and Ramundo, Francesco and Finazzi, Maria Chiara and Rambaldi, Alessandro and Vannucchi, Alessandro M},
title = {Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy},
journal = {British Journal of Haematology},
year = {2024},
volume = {205},
number = {6},
pages = {2287--2294},
doi = {10.1111/bjh.19813}
}
EUVIMED